Help advance real-world understanding of myasthenia gravis
Join the VRMG clinician network and invite patients to contribute to a long-term registry designed to improve research and patient outcomes.
It takes less than a minute to express interest.
Simply enter your details below and our team will contact you with next steps.
What happens after you register?
Once you submit your interest, our team will guide you through a short four step onboarding process.
Step 1
Sign the participation agreement
Step 2
Receive patient recruitment materials
Step 3
Start referring patients
Step 4
Access dashboards and co-author publications
Refer patients, explore insights and contribute to publications
What participation involves
Clinicians can participate in the registry by
- Inviting patients with myasthenia gravis to join the registry through handing out our patient recruitment postcards
Patients complete surveys independently through the registry platform.
About the VRMG registry
The Vitaccess Real MG Registry is a longitudinal observational registry designed to better understand myasthenia gravis, its treatment, and its impact on patients’ daily lives and quality of life.
The registry combines:
The registry combines:
- Patient-reported outcomes
- Healthcare professional input
- Medical record data
This integrated approach allows researchers to generate a richer understanding of real-world MG outcomes.
Duration: up to 10 years.
Patient eligibility
Patients may participate if they:
- Are 18 years or older
- Have a confirmed diagnosis of myasthenia gravis
- Live in the United States, United Kingdom, Italy or Spain
- Have access to a smartphone, tablet, laptop or computer
- Are not currently enrolled in a clinical trial at the time of registry enrolment.
- The registry has been approved by Salus IRB. A description of this registry is available on https://clinicaltrials.gov/study/NCT06064461.
Sponsor and Scientific Advisory Board
The Vitaccess Real MG Registry is Sponsored by Vitaccess, a patient-centred research organization based in the United Kingdom.
Our Scientific Advisory Board includes clinical and patient representation, and guides development and management of the registry to ensure it is conducted to the highest level of academic rigor, and in the best interest of patients.
Our Scientific Advisory Board includes clinical and patient representation, and guides development and management of the registry to ensure it is conducted to the highest level of academic rigor, and in the best interest of patients.

Ali Habib, MD
UCI Health, CA

Prof Saiju Jacob
Birmingham University Hospital

Dr Zabeen Mahuwala
UK HealthCare, KY

Dr Kelly Gwathmey
Columbia University

Emma Ward
Patient representative, UK

Amanda Hayes
Muscular Dystrophy UK

Prof Michael Hehir
UVM Health

MGFA
Partner

Vitaccess
Sponsor